The weekly litigation news digest is live. Subscribe now
Methods For The Treatment Of Her2 Amplified Cancer - EP3033079
The patent EP3033079 was granted to Pharmacyclics on Oct 31, 2018. The application was originally filed on Aug 12, 2014 under application number EP14835935A. The patent is currently recorded with a legal status of "Revoked".
EP3033079
- Application Number
- EP14835935A
- Filing Date
- Aug 12, 2014
- Status
- Revoked
- Jun 25, 2021
- Publication Date
- Oct 31, 2018
- External Links
- Slate, Register, Google Patents
Patent Summary
Synthesis and kinase activity of a human cancer cell line that suppresses the activity of HER2 and other related signaling pathways. The cell line contains two kinase genes coding for inhibition of each kinase.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (5) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents